CN108904780A - 一种妇科凝胶剂及其制备方法 - Google Patents
一种妇科凝胶剂及其制备方法 Download PDFInfo
- Publication number
- CN108904780A CN108904780A CN201810969945.2A CN201810969945A CN108904780A CN 108904780 A CN108904780 A CN 108904780A CN 201810969945 A CN201810969945 A CN 201810969945A CN 108904780 A CN108904780 A CN 108904780A
- Authority
- CN
- China
- Prior art keywords
- phytic acid
- acid
- gynaecological
- seed
- pure water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000001879 gelation Methods 0.000 title description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 55
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000000467 phytic acid Substances 0.000 claims abstract description 55
- 229940068041 phytic acid Drugs 0.000 claims abstract description 55
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001661 Chitosan Polymers 0.000 claims abstract description 12
- 108010022355 Fibroins Proteins 0.000 claims abstract description 12
- 239000004909 Moisturizer Substances 0.000 claims abstract description 12
- 230000001333 moisturizer Effects 0.000 claims abstract description 12
- 239000003292 glue Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 10
- 238000000605 extraction Methods 0.000 claims description 19
- 241000723353 Chrysanthemum Species 0.000 claims description 18
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 241000208680 Hamamelis mollis Species 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 239000011669 selenium Substances 0.000 claims description 12
- 229940118846 witch hazel Drugs 0.000 claims description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 210000001215 vagina Anatomy 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 230000001741 anti-phlogistic effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 239000000499 gel Substances 0.000 abstract 2
- 241000209094 Oryza Species 0.000 description 10
- 206010046914 Vaginal infection Diseases 0.000 description 5
- 201000008100 Vaginitis Diseases 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000011404 female reproductive system disease Diseases 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种妇科凝胶剂及其制备方法,其中妇科凝胶剂由以下重量比配制而成:丝素蛋白2‑8%、脱乙酰壳多糖0.5‑3%、复合植酸5‑15%、透明质酸钠5‑8%、蚕丝胶蛋白3‑6%、保湿剂8‑15%、余量为纯水。本发明不仅起到杀菌消炎的作用,还可刺激阴道自身抵抗力的恢复,改善阴道干涩情况,促进阴道细胞饱满,恢复弹性,并滋润细胞,并改善因清洁不当而导致的阴道干涩问题,效果非常好。
Description
技术领域
本发明涉及一种凝胶剂,具体涉及一种妇科凝胶剂及其制备方法。
背景技术
女性生殖系统的疾病即为妇科疾病,因女性阴道生理特点和解剖结构的特殊性,弱酸性的局部环境,各种政策寄生菌群和条件致病菌相互依存、相互制约,但这些正常菌群也会转成致病菌的风险,而致病菌的出现会导致生殖道感染,造成阴道炎易反复发作,严重影响女性生殖健康。
目前针对该疾病的主要治疗措施是通过抗生素或杀菌剂治疗,通杀所有阴道细菌以彻底清洁阴道。通过治疗后的阴道往往需要很长的时间进行自我修护,更严重者会因为治疗失当而导致阴道丧失自我调节能力,阴道变得干涩,不仅炎症反复,而且影响性生活,表现为外阴阴道干燥、性交困难、反复发生阴道炎等症状。
发明内容
针对上述现有技术存在的不足,本发明的目的是提供一种妇科凝胶剂及其制备方法,在治愈阴道炎的同时,改善阴道干涩环境。
为实现上述目的,本发明采用的技术方案:一种妇科凝胶剂,由以下重量比配制而成:丝素蛋白2-8%、脱乙酰壳多糖0.5-3%、复合植酸5-15%、透明质酸钠5-8%、蚕丝胶蛋白3-6%、保湿剂8-15%、余量为纯水。
进一步地,所述复合植酸由从黄菊花种子提取出的黄菊花植酸、从金缕梅种子中提取的植酸、米糠植酸、从富硒草本咖啡豆中提取的植酸按1:3-5:4-6:3-4的质量比混合而成。
优选地,本发明的复合植酸中各种植酸提取方法如下:即将对应的黄菊花种子或金缕梅种子或米糠或富硒草本咖啡豆采用超微粉碎后,按料水重量比为1:4的比例加入纯净水浸泡30-60min,然后送入超临界流体反应装置中,并加入盐酸调节pH至2-2.5,以二氧化碳萃取和酸法萃取两者方法结合进行萃取3-5h,然后取出后过滤收集滤液而得,其中萃取温度为50-60℃、萃取压力为45-55Mpa。
本发明妇科凝胶剂的制备方法:将脱乙酰壳多糖溶于2%的乙酸溶液中,然后加入丝素蛋白、透明质酸钠、蚕丝胶蛋白、保湿剂超声波溶解后搅拌均匀,再加入复合植酸搅拌均匀,用纯水补足搅拌均匀即得成品。
本发明的保湿剂为常规的乳酸钠、丙二醇、山梨糖醇、蜂蜜等中的一种或多种按任意比例配合而成。
与现有技术相比,本发明具备的有益效果是:
(1)采用脱乙酰壳多糖和丝素蛋白相互作用,在实现缓释和控释的基础上,极易被吸收,并对炎症有很好的修复作用,并能平衡阴道菌群环境;
(2)配方各成分之间协同作用,以复合植酸等为主抑制有害菌生长,促进益生菌的生长;以丝蛋白、脱乙酰壳多糖等修复炎症部位,并增强阴道免疫和新陈代谢能力;以复合植酸、透明质酸钠、蚕丝胶蛋白等缓解阴道干涩功能,并使阴道细胞饱满,富有弹性;而保湿剂的作用形成皮肤的保护屏障,增加其润滑度,几者相互作用,从而实现阴道炎的彻底根治,并改善因清洁不当而导致的阴道干涩问题,效果非常好;
(3)复合植酸中,各种植酸协同作用,不仅起到杀菌消炎的作用,还可刺激阴道自身抵抗力的恢复,改善阴道干涩情况,促进阴道细胞饱满,恢复弹性,并滋润细胞;
(4)本发明的凝胶剂无刺激,不产生耐药性,减少不良反应的几率。
具体实施方式
现在结合具体实施例,来对本发明作进一步的阐述。
实施例一
本实施例的妇科凝胶剂,由以下重量比配制而成:丝素蛋白8%、脱乙酰壳多糖3%、复合植酸10%、透明质酸钠8%、蚕丝胶蛋白3%、保湿剂8%、余量为纯水;其中复合植酸由从黄菊花种子提取出的黄菊花植酸、从金缕梅种子中提取的植酸、米糠植酸、从富硒草本咖啡豆中提取的植酸按1:5: 6:4的质量比混合而成。
复合植酸中各种植酸提取方法如下:即将对应的黄菊花种子或金缕梅种子或米糠或富硒草本咖啡豆采用超微粉碎后,按料水重量比为1:4的比例加入纯净水浸泡60min,然后送入超临界流体反应装置中,并加入盐酸调节pH至2-2.5,以二氧化碳萃取和酸法萃取两者方法结合进行萃取5h,然后取出后过滤收集滤液而得,其中萃取温度为60℃、萃取压力为55Mpa。
制备方法:将脱乙酰壳多糖溶于2%的乙酸溶液中,然后加入丝素蛋白、透明质酸钠、蚕丝胶蛋白、保湿剂超声波溶解后搅拌均匀,再加入复合植酸搅拌均匀,用纯水补足搅拌均匀即得成品。
实施例二
本实施例的妇科凝胶剂,由以下重量比配制而成:丝素蛋白5%、脱乙酰壳多糖2%、复合植酸8%、透明质酸钠5%、蚕丝胶蛋白5%、保湿剂15%、余量为纯水;其中复合植酸由从黄菊花种子提取出的黄菊花植酸、从金缕梅种子中提取的植酸、米糠植酸、从富硒草本咖啡豆中提取的植酸按1:4:4:4的质量比混合而成。
复合植酸中各种植酸提取方法如下:即将对应的黄菊花种子或金缕梅种子或米糠或富硒草本咖啡豆采用超微粉碎后,按料水重量比为1:4的比例加入纯净水浸泡30min,然后送入超临界流体反应装置中,并加入盐酸调节pH至2-2.5,以二氧化碳萃取和酸法萃取两者方法结合进行萃取4h,然后取出后过滤收集滤液而得,其中萃取温度为60℃、萃取压力为50Mpa。
本实施例的制备方法如实施例一。
实施例三
本实施例的妇科凝胶剂,由以下重量比配制而成:丝素蛋白5%、脱乙酰壳多糖2%、复合植酸15%、透明质酸钠5%、蚕丝胶蛋白6%、保湿剂10%、余量为纯水;其中复合植酸由从黄菊花种子提取出的黄菊花植酸、从金缕梅种子中提取的植酸、米糠植酸、从富硒草本咖啡豆中提取的植酸按1:3: 6:3的质量比混合而成。
复合植酸中各种植酸提取方法如下:即将对应的黄菊花种子或金缕梅种子或米糠或富硒草本咖啡豆采用超微粉碎后,按料水重量比为1:4的比例加入纯净水浸泡50min,然后送入超临界流体反应装置中,并加入盐酸调节pH至2-2.5,以二氧化碳萃取和酸法萃取两者方法结合进行萃取3h,然后取出后过滤收集滤液而得,其中萃取温度为60℃、萃取压力为45Mpa。
本实施例的制备方法如实施例一。
实施例四
本实施例的妇科凝胶剂,由以下重量比配制而成:丝素蛋白2%、脱乙酰壳多糖0.5%、复合植酸5%、透明质酸钠8%、蚕丝胶蛋白3%、保湿剂8%、余量为纯水;其中复合植酸由从黄菊花种子提取出的黄菊花植酸、从金缕梅种子中提取的植酸、米糠植酸、从富硒草本咖啡豆中提取的植酸按1:5:4:3的质量比混合而成。
复合植酸中各种植酸提取方法如下:即将对应的黄菊花种子或金缕梅种子或米糠或富硒草本咖啡豆采用超微粉碎后,按料水重量比为1:4的比例加入纯净水浸泡45min,然后送入超临界流体反应装置中,并加入盐酸调节pH至2-2.5,以二氧化碳萃取和酸法萃取两者方法结合进行萃取4h,然后取出后过滤收集滤液而得,其中萃取温度为50℃、萃取压力为50Mpa。
本实施例的制备方法如实施例一。
一、对本发明的凝胶剂作抑菌试验。
将实施例1-4制备的妇科凝胶剂对金黄色葡萄球菌、大肠杆菌、白色念球菌进行5/8/15min的作用,其结果如表一所示:
表一
由表一可看出,本发明凝胶对阴道炎常规的感染菌,如金黄色葡萄球菌、大肠杆菌、白色念球菌的平均抑菌率达89%以上。
此外,对应用本发明实施例二凝胶剂的80名年龄在28-40岁有性生活史的患者进行为期90天的跟踪,患者每天使用2次,每次5g,并由患者口述本发明应用后的效果,其中痊愈表示自觉症状消失,有效表示自觉症状减轻,无效表示自觉正常无改善。其汇总后的数据如下表二:
从上表二可看出,本发明的凝胶剂在改善阴道环境有效率达98%以上,并在改善因清洁不当而导致的阴道干涩问题上有效率达96%以上,效果非常好。
最后应说明的是,上述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中不乏技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应在本发明的保护范围内。
Claims (4)
1.一种妇科凝胶剂,由以下重量比配制而成:丝素蛋白2-8%、脱乙酰壳多糖0.5-3%、复合植酸5-15%、透明质酸钠5-8%、蚕丝胶蛋白3-6%、保湿剂8-15%、余量为纯水。
2.根据权利要求1所述的妇科凝胶剂,其特征在于,所述复合植酸由从黄菊花种子提取出的黄菊花植酸、从金缕梅种子中提取的植酸、米糠植酸、从富硒草本咖啡豆中提取的植酸按1:3-5:4-6:3-4的质量比混合而成。
3.根据权利要求2所述的妇科凝胶剂,其特征在于,本发明的复合植酸中各种植酸提取方法如下:即将对应的黄菊花种子或金缕梅种子或米糠或富硒草本咖啡豆采用超微粉碎后,按料水重量比为1:4的比例加入纯净水浸泡30-60min,然后送入超临界流体反应装置中,并加入盐酸调节pH至2-2.5,以二氧化碳萃取和酸法萃取两者方法结合进行萃取3-5h,然后取出后过滤收集滤液而得,其中萃取温度为50-60℃、萃取压力为45-55Mpa。
4.根据权利要求1或2或3所述的妇科凝胶剂的制备方法,其特征在于,将脱乙酰壳多糖溶于2%的乙酸溶液中,然后加入丝素蛋白、透明质酸钠、蚕丝胶蛋白、保湿剂超声波溶解后搅拌均匀,再加入复合植酸搅拌均匀,用纯水补足搅拌均匀即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810969945.2A CN108904780B (zh) | 2018-08-24 | 2018-08-24 | 一种妇科凝胶剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810969945.2A CN108904780B (zh) | 2018-08-24 | 2018-08-24 | 一种妇科凝胶剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108904780A true CN108904780A (zh) | 2018-11-30 |
CN108904780B CN108904780B (zh) | 2022-03-15 |
Family
ID=64406006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810969945.2A Active CN108904780B (zh) | 2018-08-24 | 2018-08-24 | 一种妇科凝胶剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108904780B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114903801A (zh) * | 2021-06-17 | 2022-08-16 | 苏州鑫斯达医疗科技有限公司 | 一种丝蛋白妇科凝胶及其制备方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1366025A (zh) * | 2001-01-16 | 2002-08-28 | 黄付平 | 从米糠(麸皮)中提取植酸的方法 |
WO2006133048A2 (en) * | 2005-06-03 | 2006-12-14 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
CN101791319A (zh) * | 2010-04-07 | 2010-08-04 | 北京欧凯纳斯科技有限公司 | 女性阴部护理品 |
CN102225950A (zh) * | 2011-05-05 | 2011-10-26 | 吉林农业大学 | 超临界co2制取植酸钙镁的方法 |
CN102626524A (zh) * | 2012-05-04 | 2012-08-08 | 江西中兴汉方药业有限公司 | 壳聚糖妇科抗菌凝胶及其制备方法 |
WO2013038402A1 (en) * | 2011-09-18 | 2013-03-21 | Peritech Pharma | Vaginal danazol combined with non steroidal anti inflammatory drugs (nsaids) compositions |
CN103040728A (zh) * | 2013-02-03 | 2013-04-17 | 福州乾正药业有限公司 | 一种壳聚糖妇用凝胶及其制备方法和医药应用 |
CN103316033A (zh) * | 2013-07-03 | 2013-09-25 | 康晓飞 | 一种凝胶剂及其用途 |
CN104027300A (zh) * | 2014-07-07 | 2014-09-10 | 江苏瑞京科技发展有限公司 | 一种抗菌壳聚糖凝胶剂及其制备方法 |
WO2016091778A1 (fr) * | 2014-12-12 | 2016-06-16 | Kiomed Pharma | Microbille d'hydrogel de chitosane |
WO2016120796A1 (en) * | 2015-01-27 | 2016-08-04 | Professional Dietetics S.P.A. | Compositions comprising a) chitosan, b) glycolic acid, c) carnitine and/or n-acetyl cysteine for the dermal-epidermal peeling treatment |
CN107811964A (zh) * | 2016-09-09 | 2018-03-20 | 国家卫生计生委科学技术研究所 | 可生物降解并实现定量给药的抗菌避孕凝胶 |
-
2018
- 2018-08-24 CN CN201810969945.2A patent/CN108904780B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1366025A (zh) * | 2001-01-16 | 2002-08-28 | 黄付平 | 从米糠(麸皮)中提取植酸的方法 |
WO2006133048A2 (en) * | 2005-06-03 | 2006-12-14 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
CN101791319A (zh) * | 2010-04-07 | 2010-08-04 | 北京欧凯纳斯科技有限公司 | 女性阴部护理品 |
CN102225950A (zh) * | 2011-05-05 | 2011-10-26 | 吉林农业大学 | 超临界co2制取植酸钙镁的方法 |
WO2013038402A1 (en) * | 2011-09-18 | 2013-03-21 | Peritech Pharma | Vaginal danazol combined with non steroidal anti inflammatory drugs (nsaids) compositions |
CN102626524A (zh) * | 2012-05-04 | 2012-08-08 | 江西中兴汉方药业有限公司 | 壳聚糖妇科抗菌凝胶及其制备方法 |
CN103040728A (zh) * | 2013-02-03 | 2013-04-17 | 福州乾正药业有限公司 | 一种壳聚糖妇用凝胶及其制备方法和医药应用 |
CN103316033A (zh) * | 2013-07-03 | 2013-09-25 | 康晓飞 | 一种凝胶剂及其用途 |
CN104027300A (zh) * | 2014-07-07 | 2014-09-10 | 江苏瑞京科技发展有限公司 | 一种抗菌壳聚糖凝胶剂及其制备方法 |
WO2016091778A1 (fr) * | 2014-12-12 | 2016-06-16 | Kiomed Pharma | Microbille d'hydrogel de chitosane |
WO2016120796A1 (en) * | 2015-01-27 | 2016-08-04 | Professional Dietetics S.P.A. | Compositions comprising a) chitosan, b) glycolic acid, c) carnitine and/or n-acetyl cysteine for the dermal-epidermal peeling treatment |
CN107811964A (zh) * | 2016-09-09 | 2018-03-20 | 国家卫生计生委科学技术研究所 | 可生物降解并实现定量给药的抗菌避孕凝胶 |
Non-Patent Citations (2)
Title |
---|
JORGE A.M. DELEZUK等: "Silk fibroin organization induced by chitosan in layer-by-layer films: Application as a matrix in a biosensor", 《CARBOHYDRATE POLYMERS》 * |
唐春红: "天然抗氧剂复配常用配料及作用", 《天然防腐剂与抗氧化剂》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114903801A (zh) * | 2021-06-17 | 2022-08-16 | 苏州鑫斯达医疗科技有限公司 | 一种丝蛋白妇科凝胶及其制备方法 |
CN114903801B (zh) * | 2021-06-17 | 2024-08-27 | 苏州鑫斯达医疗科技有限公司 | 一种丝蛋白妇科凝胶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108904780B (zh) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101797304B (zh) | 一种调节女性阴道微生态的凝胶 | |
CN106466454A (zh) | 一种预防及治疗妇科炎症的凝胶剂 | |
CN106727849A (zh) | 一种妇科凝胶 | |
CN110090195A (zh) | 一种女性私密护理凝胶及其制备方法 | |
CN101953860A (zh) | 一种缓解痔疮症状的湿巾及其生产方法 | |
CN103394012A (zh) | 医用皮肤消毒液 | |
CN109568249A (zh) | 一种女性私密养护抑菌凝胶及其制备方法和应用 | |
CN110051773A (zh) | 一种含有金花茶具有抗菌修复腔道炎症的凝胶及其制法 | |
CN108904780A (zh) | 一种妇科凝胶剂及其制备方法 | |
CN105999224B (zh) | 一种仿生型妇科洗液及其制备方法 | |
CN102335462A (zh) | 一种纳米碘壳聚糖宫颈治疗膜剂及膜的制备方法 | |
CN109771595A (zh) | 一种用于治疗妇科炎症的中药组合物及其制备方法 | |
CN108938703A (zh) | 快速抗菌的妇科凝胶 | |
CN107551090A (zh) | 一种滋养修复凝胶 | |
CN101757119B (zh) | 一种治疗阴道炎的药物组合物、凝胶剂及其制备方法 | |
CN107308104A (zh) | 一种妇科凝胶的制备方法 | |
CN109432204B (zh) | 一种银离子喷雾及其制备方法 | |
CN103599437B (zh) | 一种治疗阴道炎的中药药液 | |
CN108066278B (zh) | 一种含有壳寡糖的妇科用凝胶及其制备方法 | |
CN105902686A (zh) | 一种含有纳米碳晶的原位凝胶眼药水及其制备方法 | |
CN105395527A (zh) | 一种海洋生物护伤喷膜剂的制备方法 | |
CN110193004A (zh) | 含生物抑菌肽的女性抑菌凝胶及其制备方法 | |
CN108355130A (zh) | 一种治疗牛皮癣的温敏型胶原复合消炎凝胶喷剂及其制备方法 | |
CN110141609A (zh) | 一种用于治疗小儿眼角裂的药膏及其制备方法 | |
CN114712482B (zh) | 一种含虾青素的洁阴抑菌凝胶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 415701 Innovation and Entrepreneurship Industrial Park, Qinglin Village, Qinglin Hui Uyghur Township, Taoyuan County, Changde City, Hunan Province Patentee after: Hunan Jinpeng Medical Equipment Co.,Ltd. Address before: 415000 Hunan Changde Taoyuan County Qinglin Hui Uygur Township Qinglin village innovation and entrepreneurship Industrial Park Patentee before: HUNAN KING PENG MEDICAL APPLIANCES CO.,LTD. |